Home / Blog

DelveInsight Blog

Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.

Search by Categories

Analyzing the Potential of AAV2-GDNF Gene Therapy in Parkinson’s Disease Treatment: Insights from Phase Ib Trial Data

AB-1005 represents a pioneering gene therapy utilizing an adeno-associated viral vector serotype 2 (AAV2) to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene directly into the brain. This innovative technique allows for precise and sustained expression of GDNF, offering promising therapeutic potential for conditions like Parkinson’s disease characterized by the degeneration of midbrain dopaminergic neurons. GDNF, a member of the transforming growth factor-β superfamily, has demonstrated remarkable neuroprotective effects in preclinical studies. By promoting the survival and differentiation of dopaminergic neurons in the midbrain, GDNF holds the promise…
aav2-gdnf-gene-therapy-phase-ib-trial-data

LIBERVANT Buccal Film: Pioneering Pediatric Epilepsy Treatment Advancements

LIBERVANT, a diazepam buccal formulation based on PharmFilm technology serves as a beacon of hope, offering convenient alternatives to existing device-based products, for managing acute repetitive seizure emergencies in young patients. LIBERVANT utilizes "fast-melt strips" for "buccal delivery of diazepam, offering promises to rewrite the narrative of acute repetitive seizure emergencies, ushering in an era of renewed optimism and therapeutic advancement. At the 76th Annual Meeting of the American Academy of Neurology (AAN) 2024 in Denver from April 13 to 18, Aquestive Therapeutics presented an abstract for the crossover study data evaluating the…
libervant-for-pediatric-epilepsy-treatment

Analyzing ABBV-951 for Parkinson’s Disease: A Promise in Addressing Motor Fluctuations and Enhancing Quality of Life

ABBV-951, an innovative investigational drug developed by AbbVie, offers hope for patients with advanced Parkinson's disease by providing continuous subcutaneous delivery of carbidopa and levodopa prodrugs, aiming to address motor fluctuations more effectively than oral medication. Leveraging its small molecule design and targeted action on dopamine receptors, ABBV-951 presents a promising approach to managing the challenging symptoms of Parkinson's disease, including tremors, muscle rigidity, and impaired movement, offering potential improvements in patients' quality of life. Parkinson's disease (PD) poses significant challenges as it progresses, with motor fluctuations and dyskinesias often…
abbv-951-for-parkinsons-disease

Trending

dayvigo-phase-iii-study-e2006-g000-304
DAYVIGO’s Promise at AAN 2024: Elevating Morning Alertness and Sleep Qu...

DAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who…

Find out more
bhv-7000s-potential-in-epilepsy
Unveiling Boundless Horizons: Unlocking BHV-7000’s Potential in Epilepsy

Biohaven with BHV-7000 underscores unwavering commitment to neurology and to addressing unmet patient needs, by…

Find out more
fenebrutinib-phase-ii-study-fenopta
Promising Efficacy and Safety of Fenebrutinib in Relapsing Multiple Sclerosis...

Fenebrutinib distinguishes itself from other BTK inhibitors through its unique reversible mechanism. It aims to…

Find out more
medtech-news-for-iveacare-cerenovus-cochlear-immunovia
iVEAcare’s $27.5 Million Series A Funding; AI Medical Service Joint Research ...

iVEAcare Launched $27.5 Million Series A Funding from Leading Medtech Investors On April 24, 2024,…

Find out more
ravulizumab-nmosd-treatment-analysis
Ravulizumab Outshines Competitors: Insights from NMOSD Treatment Analysis

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with…

Find out more
riliprubart-phase-ii-results
Riliprubart’s Ascendancy: Phase II Results Illuminate Path Forward for ...

Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to…

Find out more

Artificial Intelligence (AI) in Mental Health
Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

FDA granted accelerated approval to Lilly’s Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma patients.

Find More
dermatomyositis-treatment

Unraveling the Complexities of Dermatomyositis Treatment: A Comprehensive Review and Future Perspectives

Read More
stelara-biosimilar-wezlana

Could Amgen’s Biosimilar Wezlana Pose a Challenge to Johnson & Johnson’s Stelara

Read More
Cryotherapy Market Analysis

Navigating the Booming Cryotherapy Market and Its Future Outlook

Read More
label-expansion-of-xtandi-and-keytruda

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

Read More

voquezna-for-gerd-treatment
Phathom Secures Dual FDA Approvals for Voquezna Following Impurity Setback

Within a three-day period, Phathom Pharmaceuticals achieves dual FDA approvals for Voquezna, its groundbreaking heartburn medication.

Find More
recent-developments-in-nsclc-treatment
The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations

The evolving landscape of NSCLC treatment presents significant market opportunities for pharmaceutical companies to secure their place.

Find More
Rehabilitation Equipment Market Analysis
Evaluating the Growing Role of Rehabilitation Equipment in Revitalizing Lives and Improving the Treatment Outcome

Rehabilitation equipment, a cornerstone in the realm of healthcare, has undergone ...

Find More

Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing and commercialisation presence in Europe, wanted to assess the launch readiness of competitors involved in the same arena for strategic positioning of their product. They wished to identify and evaluate the launch timelines, geographies of launch, First Launch company, commercial readiness, and salesforce of competitors.

Find More
Product Assessment
Product Assessment

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

A large pharma client was working to develop their cyclophosphamide API and FD and was interested to assess competitive products in the same domain and area to provide benchmarking of their asset in comparison to their competitors The client requested periodic reports (Quarterly) on the developmental milestones of competitor companies, thorough assessment of the competitor products through Secondary and Primary CI inputs.

Find More
Asset Prioritization
Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

A mid-sized pharma client was working to develop their asset portfolio and was interested in assessing best possible asset for atrial fibrillation for future development and licensing needs. The client requested evidence-based priorities in assets and products for Phase II development in atrial fibrillation, through potential licensing collaborations. Also, the client wanted to prioritise research efforts to determine the best possible asset to leverage their research portfolio.

Find More
Out Licensing Opportunity
Out-Licensing Opportunity

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from across the globe. They wished to identify a potential list of companies, to become a fit for their neonatal high quality MSCs and can prove to be a good business partner as a licensee for their proprietary “API” of the stem cell therapy domain.

Find More
In Licensing Opportunity
In-Licensing Opportunity

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

A large client based in the USA, involved in drug delivery devices, with effective marketing and commercialisation presence across the globe, wanted to in-license potential dMTS based drug delivery asset from companies involved in microneedle technology research for delivering therapeutic products. They wished to identify and assess the technological competencies, clinical capabilities and commercial readiness of potential companies with a novel and non-invasive way of delivering drugs, which can include a variety of drugs/vaccines in their patch and successfully develop the product for commercial purposes, were of client’s interest.

Find More
Go To Market Strategy
Go-To-Market Strategy

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

A medium pharmaceutical client based in the United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe through Competitive Assessment of their EU based competitors in the same area of interest. They wished to identify manufacturing sites, logistic operations, distribution network, salesforce assessment and their sales targets.

Find More

See How We Do It

Our Consulting Services
Consulting Services

Optimized, competent, and dependable solutions to tackle fast-paced pharma market challenges.

Our Pharma Market Reports
Pharma Market Reports

Credible, data-driven, & analytical pharma & biotech market research & analysis for a holistic understanding.

Our MedTech Insights
MedTech Insights

Clinical solutions for vastly expanding diagnostics, digital therapeutics, & the MedTech industry.